X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Through the acquisition, XOMA will get access to KIN-2787 (exarafenib), which is a potent and selective investigational small molecule pan-RAF inhibitor that is being evaluated for the BRAF/NRAS-mutated advanced or metastatic solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: XOMA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 16, 2024
Details:
The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), in the EU.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 15, 2023
Details:
Braftovi (encorafenib) + Mektovi (binimetinib) is approved for the treatment of adult patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC), who are either treatment naïve or have received prior therapy.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Braftovi (Encorafenib) is an oral small molecule BRAF kinase inhibitor and is approved in combination with Mektovi (binimetinib) in patients with BRAF V600E-mutant metastatic non-small cell lung cancer.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
KIN-2787 (exarafenib) is an orally administered, potent and selective investigational small molecule pan-RAF inhibitor, designed to target BRAF Class II and Class III alterations, it is a potential treatment for NRAS mutation-positive melanoma.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
Braftovi (encorafenib) is an oral small molecule BRAF kinase inhibitor and MEKTOVI (binimetinib) is an oral small molecule MEK inhibitor which target key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK), for patients with metastatic non-small cell lung cancer.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
KIN-2787, is an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kinnate Biopharma
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 21, 2023
Details:
KIN-2787 (exarafenib), is an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
KIN-2787, a pan-RAF inhibitor, achieved meaningful exposures that were dose proportional and exceeded the predicted efficacious thresholds based on preclinical models. KIN-2787 cleared the predicted efficacious dose at 300 mg bid.
Lead Product(s): KIN-2787,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
KIN-2787 is an orally available, potent and selective small molecule pan-RAF inhibitor being evaluated in KN-8701, an ongoing Phase 1 global clinical trial in patients with solid tumors harboring BRAF alterations or who have NRAS mutant melanoma.
Lead Product(s): KIN-2787,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
OKI-179 is a novel, oral Class I histone deacetylase (HDAC) inhibitor for the potential treatment of a wide range of solid and hematological malignancies.
Lead Product(s): OKI-179,Binimetinib
Therapeutic Area: Oncology Product Name: OKI-179
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
Braftovi (encorafenib) is an oral small-molecule BRAF kinase inhibitor and binimetinib is an oral small-molecule MEK inhibitor that targets key enzymes in the MAPK signalling pathway (RAS-RAF-MEK-ERK).
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Organisation for Research and Treatment of Cancer
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Daily KIN-2787 treatment resulted in tumor growth inhibition in human melanoma xenograft models bearing Class I, II and III BRAF alterations as well as NRAS mutation and was associated with MAPK pathway suppression.
Lead Product(s): KIN-2787,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
OKI-179 combined with binimetinib in NRAS-mutated melanoma or combined with binimetinib + encorafenib in BRAF-mutated colorectal xenografts showed significantly increased regressions compared to either single agent following two weeks of dosing.
Lead Product(s): OKI-179,Binimetinib
Therapeutic Area: Oncology Product Name: OKI-179
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
In preclinical studies, KIN-2787, small molecule pan-RAF inhibitor has demonstrated its potential as a promising next-generation RAF inhibitor with unique properties that have demonstrated potent activity against a variety of oncogenic BRAF-driven cancers.
Lead Product(s): KIN-2787,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
OKI-179, a novel oral Class I histone deacetylase inhibitor for treatment of wide range of solid and hematological malignancies, increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma.
Lead Product(s): OKI-179,Binimetinib
Therapeutic Area: Oncology Product Name: OKI-179
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Colorado
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
KIN-2787 is a promising next-generation RAF inhibitor with demonstrated capabilities in overcoming well-characterized resistance mechanism, also has shown potent activity against a variety of oncogenic BRAF-driven lung cancers in preclinical studies.
Lead Product(s): KIN-2787,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with previously treated metastatic CRC with a BRAF V600E mutation.
Lead Product(s): Cetuximab,Binimetinib
Therapeutic Area: Oncology Product Name: Erbitux
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
ERBITUX is the first anti-EGFR antibody approved, in combination with encorafenib, for this indication and is based on results from Pfizer's BEACON CRC trial, Phase 3 trial to specifically study patients with previously treated metastatic CRC with a BRAF V600E mutation.
Lead Product(s): Cetuximab,Binimetinib
Therapeutic Area: Oncology Product Name: Erbitux
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
The partnership includes the planning, design and execution of a large Phase 3 study of Braftovi (encorafenib) investigating the use of BRAF and MEK targeted therapies to reduce the risk of relapse in this patient population, currently under approval with authorities.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EORTC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 29, 2021
Details:
In the Phase 1/2a clinical trial of the SHP2 inhibitor JAB-3312 in combination with the PD-1 antibody Pembrolizumab and the MEK inhibitor Binimetinib, the first two patients have been dosed, triggering a US$20 million milestone payment from AbbVie.
Lead Product(s): JAB-3312,Binimetinib
Therapeutic Area: Oncology Product Name: JAB-3312
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $65.0 million Upfront Cash: $45.0 million
Deal Type: Collaboration June 18, 2021
Details:
Darovasertib and binimetinib combination reports 2 partial responses (PR), including one confirmed partial response, out of nine evaluable patients with at least 2 post-baseline scans (22%) in MUM; 1 PR patient (-40.5%) is awaiting a confirmatory scan.
Lead Product(s): Darovasertib,Binimetinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Details:
The agreement aims at supporting the clinical proof of concept study for MEKTOVI® (binimetinib) in combination with OKI-179, a highly potent and tolerable Class I HDAC inhibitor currently in Phase I for the treatment of NRAS melanoma.
Lead Product(s): OKI-179,Binimetinib
Therapeutic Area: Oncology Product Name: OKI-179
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: OnKure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 21, 2020
Details:
IDEAYA and Pfizer will form a Joint Development Committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties.
Lead Product(s): Darovasertib,Binimetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ideaya Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 18, 2020
Details:
53 patients enrolled in Phase 1/2 monotherapy study, including 49 in MUM and 4 in Cutaneous Melanoma, from earlier-reported 40 patients in December 2019.
Lead Product(s): Darovasertib,Binimetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
